TY - JOUR
T1 - The good, bad, and the ugly of regenerative therapies for erectile dysfunction
AU - Campbell, Jeffrey D.
AU - Milenkovic, Uros
AU - Usta, Mustafa Faruk
AU - Albersen, Maarten
AU - Bivalacqua, Trinity J.
N1 - Publisher Copyright:
© Translational Andrology and Urology. All rights reserved.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Erectile dysfunction (ED) is a common condition which reduces quality of life of both patients and their partners, and is a significant health care expense every year. Although phosphodiesterase type-5 inhibitors are the current first-line treatment for men with ED, they are limited by their on-demand dosing, intolerance, and variable efficacy in complex patient populations such as men with multiple medical comorbidities or ED after pelvic surgery. Regenerative medicine has been introduced and investigated in andrology as an encouraging strategy to restore diseased erectile tissue structure and function. Novel regenerative therapies for ED are controversial but are perceived to offer a durable and safe tissue restorative approach to act as a long-term solution to this cumbersome disease process. Here, we review platelet-rich plasma, amniotic fluid membranes, low-intensity extracorporeal shockwave therapy, and stem cell therapy as regenerative strategies to treat ED. Most of these approaches have preclinical and occasionally clinical data to support their ongoing investigation; however, none of these treatments are currently supported for use in ED patients outside of clinical trials.
AB - Erectile dysfunction (ED) is a common condition which reduces quality of life of both patients and their partners, and is a significant health care expense every year. Although phosphodiesterase type-5 inhibitors are the current first-line treatment for men with ED, they are limited by their on-demand dosing, intolerance, and variable efficacy in complex patient populations such as men with multiple medical comorbidities or ED after pelvic surgery. Regenerative medicine has been introduced and investigated in andrology as an encouraging strategy to restore diseased erectile tissue structure and function. Novel regenerative therapies for ED are controversial but are perceived to offer a durable and safe tissue restorative approach to act as a long-term solution to this cumbersome disease process. Here, we review platelet-rich plasma, amniotic fluid membranes, low-intensity extracorporeal shockwave therapy, and stem cell therapy as regenerative strategies to treat ED. Most of these approaches have preclinical and occasionally clinical data to support their ongoing investigation; however, none of these treatments are currently supported for use in ED patients outside of clinical trials.
KW - Amniotic fluid
KW - Chorion grafts
KW - Erectile dysfunction (ed)
KW - Low-intensity extracorporeal shockwave treatment
KW - Platelet-rich plasma submitted jun 01, 2019. accepted for publication oct
KW - Stem cell therapy
UR - http://www.scopus.com/inward/record.url?scp=85081693376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081693376&partnerID=8YFLogxK
U2 - 10.21037/tau.2019.10.06
DO - 10.21037/tau.2019.10.06
M3 - Review article
C2 - 32257866
AN - SCOPUS:85081693376
SN - 2223-4683
VL - 9
SP - S252-S261
JO - Translational Andrology and Urology
JF - Translational Andrology and Urology
ER -